The 340B Drug Pricing Program: High 5 Issues to Know

The 340B Drug Pricing Program continues to supply important assist for coated entities, though this system is topic to ongoing scrutiny and congressional, judicial, and {industry} pressures. Sure key steerage paperwork issued by the Well being Sources and Providers Administration (HRSA) had been not too long ago rejected by the courts, and extra instances are pending. Congress might in the end resolve the route of this system. With the 340B program remaining a key financial driver for a lot of within the oncology house – as highlighted on the September 2024 Most cancers Care Enterprise Alternate assembly in Boston, listed below are the important thing issues to know in September 2024:

Huge Pharma Restricts Use of Contract Pharmacy, Introduces Rebate System for Accessing 340B

On August 23, Johnson & Johnson (J&J) launched a brand new system, to be efficient October 15, 2024, beneath which J&J will not course of wholesaler chargebacks for the 340B ceiling value on purchases of STELARA or XARELTO by 340B DSH hospitals. As a substitute, Lined Entities might want to buy these medicine via wholesalers at business value, and apply for rebates via a brand new declare platform to be offered by J&J. That is solely the most recent method drug producers try to switch the 340B program. Beforehand, greater than 20 drug producers established insurance policies that restricted using contracted retail pharmacies to distribute 340B medicine – which restrictions had been challenged in court docket and not too long ago upheld by each the Third Circuit and the DC Circuit[1]. The producers successfully argued that prior steerage issued by HRSA was not authoritative and was not grounded within the 340B statute, which is silent on strategies of distribution of 340B medicine. One different circuit resolution stays pending in addition to a number of instances nonetheless in district courts.

Growth of Affected person Eligibility

HRSA’s efforts to rein in 340B affected person eligibility determinations by limiting program entry to conditions the place “the well being care service ensuing within the prescription was initiated by the ‘coated entity’” had been undermined by the 2023 ruling Genesis Healthcare, Inc. v. Becerra.[2] The Genesis court docket dominated that HRSA’s interpretation of the time period “affected person” included necessities that had been inconsistent with the frequent (dictionary) which means of the time period “affected person” and subsequently with the 340B statute. Though technically solely binding on the Genesis plaintiffs, Genesis signifies that coated entities have extra flexibility to ascertain insurance policies defining who their sufferers are and the circumstances wherein they will obtain 340B medicine. The federal government is at present contemplating easy methods to modify its procedures for auditing affected person eligibility points for different coated entities.

Refund of $1.96 billion in Previous Fee Cuts Started, however Medicare Benefit is Excluded

Wrapping up years of litigation specializing in Medicare OPPS fee reductions on 340B coated medicine from 2018-2022, the Facilities for Medicare & Medicaid Providers (CMS) will make lump sum funds of $9 billion to affected 340B hospitals to treatment the illegal fee cuts.[3] To take care of finances neutrality, CMS may also apply a 0.5% discount of funds to all OPPS hospitals starting in 2026. The answer doesn’t handle funds to 340B hospitals via Medicare Benefit plans. A ensuing go well with alleges that CMS breached its obligations by unlawfully decreasing funds owed to them for almost 5 years, leading to a windfall for the plans.[4]

Delays On Including New 340B Eligible Hospital Websites Have Been Re-introduced

HRSA instructed hospital coated entities that they as soon as once more want to attend to register new hospital outpatient location till after the placement is recognized on a filed Medicare price report. This coverage may end up in delays of accessing 340B of as much as 21 months after the placement is opened. The coverage had been waived through the COVID-19 public well being emergency and not too long ago reinstated; the reintroduction of the coverage is being challenged in court docket by a bunch of 44 well being techniques.[5]

Rising Litigation Doubtless

Lined entities which were working to adjust to HRSA steerage needs to be monitoring these instances, which signify a major shift within the 340B panorama. With the Supreme Court docket’s current resolution in Loper Vivid Enterprises v. Raimondo[6] making it simpler to problem company steerage, it’s anticipated that courts will proceed to play a major function in figuring out the way forward for the 340B program. 340B entities also needs to hold a detailed eye on HRSA’s new Administrative Dispute Decision (ADR) course of for listening to disputes associated to the 340B Program, which can start issuing opinions on key areas.[7]

Legislative Exercise is Rising

Congress and state legislatures are additionally inspecting the 340B program. The U.S. Congress has held a number of hearings and is evaluating a wide range of payments that may affect 340B. Many states have additionally handed legal guidelines geared toward defending 340B coated entities.

Foley is right here that can assist you handle the brief and long-term impacts within the wake of regulatory and legislative adjustments within the space of 340B. We have now the sources that can assist you navigate these and different essential authorized concerns associated to enterprise operations and industry-specific points. Please attain out to the authors, your Foley relationship companion, or to our Well being Care Follow Group and Well being Care & Life Sciences Sector with any questions.

[1] Sanofi Aventis U.S. LLC v. United States HHS, 58 F.4th 696 (3d Cir. 2024); Novartis Prescribed drugs Company v. Johnson and Becerra, 102 F.4th 452  (DC Cir. 2024).

[2] Genesis Well being Care, Inc. v. Becerra, 701 F. Supp 3d 312 (D.S.C 2023).

[3] See 88 Fed. Reg. 77150 (Nov. 2023)

[4] Baptist Well being v. Well being Worth Administration, Inc., et. al., Case No. 2:24-cv-00077-SMD (Feb. 2024).

[5] Albany Med System v. Becerra, Case No. 1:2024cv01258.

[6] Loper Vivid Enterprises v. Raimondo, No. 22-451 (June 28, 2024), along with Relentless, Inc. v. Division of Commerce, No. 22-1219, 603 U.S. _____ (2024),144 S. Ct. 2244 (2024).

[7] Dept. Of H. & Hum. Svcs, 340B Drug Pricing Program; Administrative Dispute Decision Regulation, RIN 0906-AB28, 89 Fed. Reg. 28643 (Apr. 19, 2024).